#USA #Seoul #FDA Clearance #STARmed #Thyroid Nodule

STARMED Achieves FDA Clearance for Thyroid Nodule Ablation

In a groundbreaking announcement that underscores the advancement in minimally invasive treatment technologies, STARMED has received the prestigious 510(k) clearance from the United States Food and Drug Administration (FDA) for its thyroid nodule ablation system. This significant achievement, confirmed to be effective from May 26, 2026, designates the system specifically for ultrasound-guided percutaneous ablation of benign thyroid nodules in adult patients.

STARMED has distinguished itself as an industry leader by being the first global company to receive FDA approval for a technology specifically aimed at thyroid nodule ablation. This achievement has set a new benchmark for healthcare providers looking to incorporate radiofrequency ablation into their practices. According to STARMED’s CEO, Henry Shin, the clearance marks a pivotal moment for medical professionals and institutions who are assessing the viability of thyroid radiofrequency ablation.

The FDA's precise naming of the approval highlights the clear application and purpose of the system, which is exclusive to adult patients suffering from cytologically confirmed benign thyroid nodules. The specificity in the clearance is vital, as it differentiates the device from general soft-tissue ablation technologies, ensuring that clinicians are aware of the precise protocol to follow, including patient demographics and eligibility criteria.

The STAR RF Electrode, part of this FDA-cleared system, is a sophisticated radiofrequency ablation electrode designed to enhance precision under ultrasound guidance. Coupled with the VIVA RF Electrode, which features an adjustable active tip, clinicians can cater the ablation size to the specific needs of each patient. This flexibility signifies a leap forward in customizing patient care, significantly impacting treatment outcomes.

Founded in 2009, STARMED has been at the forefront of developing advanced thermal ablation technologies tailored for minimally invasive procedures across a range of clinical applications, including thyroid, liver, kidney, and uterine treatments. With a commitment to clinical excellence, the company has forged partnerships with medical professionals and academic institutions worldwide, facilitating the development of its proprietary technologies through concerted efforts in research and education.

STARMED's dedication is reflected in its robust repository of clinical research evidence, which spans over 700 sources and is utilized in more than 70 countries. The company prides itself on having mentored clinicians through training programs in over ten countries, ensuring that medical professionals are well-equipped to utilize these innovative technologies.

As healthcare evolves, STARMED remains at the forefront by continuously expanding access to precise, minimally invasive thermal ablation therapies. This milestone not only enhances the treatment options available to patients but also represents a culmination of over two decades of focused research and collaboration in technology development for thyroid conditions.

For additional information about the FDA-cleared thyroid nodule ablation system, you can visit STARMED’s official site. Through ongoing research, product enhancements, and clinical partnerships, STARMED is paving the way for improved therapeutic options in the management of benign thyroid conditions, addressing the growing need for effective and patient-centered healthcare solutions.